A role for central cannabinoid and opioid systems in peripheral Δ9-tetrahydrocannabinol-induced analgesia in mice

European Journal of Pharmacology

Volumn 301, Issue 1-3, 1996, Pages 75-81

  Reche, Ignacio ^a   Fuentes, Jose A ^a   Ruiz Gayo, Mariano ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Analgesia; Dynorphin; Nor binaltorphimine; Opioid; SR 141,716 A; 9 Tetrahydrocannabinol

Indexed keywords

CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DRONABINOL; DYNORPHIN A [1-8] ANTIBODY; KAPPA OPIATE RECEPTOR ANTAGONIST; MORPHINE; NALOXONE; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE RECEPTOR; RIMONABANT; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ARTICLE; CENTRAL NERVOUS SYSTEM; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG MECHANISM; HOT PLATE TEST; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TAIL FLICK TEST;

EID: 0029896176     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00045-3     Document Type: Article

References (41)

1. Baamonde, A., V. Daugé, M. Ruiz-Gayo, I.G. Fulga, S. Turcaud, M.C. Fournié-Zaluski and B.P. Roques, 1992, Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid δ and dopamine D1 receptor stimulation, Eur. J. Pharmacol. 216, 157.
2. Bhargava, H.N., 1976a, Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice, Psychopharmacology 49, 270.
3. 9-tetrahydrocannabinol, Eur. J. Pharmacol. 36, 259.
4. 9-tetrahydrocannabinol in the mouse, Psychopharmacology 57, 243.
5. 9β-hydroxyxexahydrocannabinol, a cannabinoid with potent antinociceptive activity: comparisons with morphine, J. Pharmacol. Exp. Ther. 200, 263.
6. Chesher G.B, C.J. Dahl, M. Everingham, D.M. Jackson, H. Marchant-Williams and G.A. Starmer, 1973, The effects of cannabinoids on intestinal motility and their antinociceptive effect in mice, Br. J. Pharmacol. 49, 588.
7. D'Amour, F.E. and D.L. Smith, 1941, A method for determining loss of pain sensation, J. Pharmacol. Exp. Ther. 72, 74.
8. Devane, W.A., F.A. Dysarz III, M.R. Johnson, L.S. Melvin and A.C. Hewlett, 1988, Determination and characterization of cannabinoid receptor in rat brain, Mol. Pharmacol. 34, 605.
9. Devane, W.A., L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, G. Griffin, D. Gibson, A. Mandelbaum, A. Etinger and R. Mechoulam, 1992, Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science 258, 1946.
10. Dewey, W.L., 1986, Cannabinoid Pharmacology, Pharmacol. Rev. 38, 151.
11. Di Marzo, V., A. Fontana, H. Cadas, S. Schinelli, G. Cimino, J.C. Schwartz and D. Pomelli, 1994, Formation and inactivation of endogenous cannabinoid anandamide in central neurons, Nature 372, 686.
12. Eddy, N.B. and D. Liembach, 1953, Synthetic analgesic (II): diethylbutenyl and dithienylbutylamines, J. Pharmacol. Exp. Ther. 107, 385.
13. Ferri, S., E. Cavicchini, P. Romualdi, E. Speroni and E. Murari, 1986, Possible mediation of catecholaminergic pathways in the antinociceptive effect of an extract of Cannabis sativa L. Psychopharmacology 89, 244.
14. Gardner, E.L. and J.H. Lowinson, 1991, Marijuana's interaction with brain reward system: Update 1991, Pharmacol. Biochem. Behav. 40, 571.
15. Haley, T.J. and W.G. McCormick, 1957, Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse, Br. J. Pharmacol. 12, 12.
16. Hayashi, G, and A.E. Takemori, 1971, The type of analgesic-receptor interaction involved in certain analgesic assays. Eur. J. Pharmacol. 16, 63.
17. Hine, B., E. Friedman, M. Torrelio and S. Gershon, 1975, Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabibol, Science 187, 443.
18. Howlett, A.C., M. Bidaut-Russell, W.A. Devane, L.S. Melvin, M.R. Johnson and M. Herkenham, 1990, The cannabinoid receptor: biochemical, anatomical and behavioural characterization, Trends Neurosci. 13, 420.
19. Hylden, J.L.K and G.L. Wilcox, 1980, Intrathecal morphine in mice: a new technique, Eur. J. Pharmacol. 67, 313.
20. 9-tetrahydrocannabinol-tolerant rats, Psychopharmacology 55, 243.
21. Litchfield, J.T. and F. Wilcoxon, 1949. A simplified method of evaluating dose-effect experiments, J. Pharmacol. Exp. Ther. 96, 99.
22. Lynn, A.B. and M. Herkenham, 1994, Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids, J. Pharmacol. Exp. Ther. 268, 1612.
23. Martin, B.R., 1985, Structural requirements for cannabinoid-induced antinociceptive activity in mice, Life Sci. 36, 1523.
24. Matsuda, L.A., S.J. Lolait, M.J. Brownstein, A.C. Young and T.I. Bonner, 1990, Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature 346, 561.
25. McLaughlin, C.R. and M.E. Abood, 1993, Developmental expression of cannabinoid receptor mRNA, Dev. Brain Res. 76, 75.
26. Munro, S., K.L. Thomas and M. Abu-Shaar, 1993, Molecular characterization of a peripheral receptor for cannabinoids, Nature 365, 61.
27. Rinaldi-Carmona, M., F. Brth, M. Héaulme, D. Shire, B. Calandra, C. Congy, S. Martínez, K.J. Maruani, G. Néliat, D. Caput, P. Ferrara, P. Soubrié, J.C. Brelière and G. Le Fur, 1994, SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor, FEBS Lett. 350, 240.
28. Sanders, J., D.M. Jackson and G.A. Starmer, 1979, Interactions among the cannabinoids iun antagonism of the abdominal constriction response in the mouse. Pharmacologia 61, 281.
29. 9-tetrahydrocannabinol and kappa opioids in mice, J. Pharmacol. Exp. Ther. 268, 1381.
30. Tallarida, R.J. and R.B. Murray, 1986, Manual of Pharmacologic Calculations with Computer Programs (Springer-Verlag), p. 53.
31. Takemori, A.E., B.Y. Ho, J.S. Naeseth and P.S. Portoghese, 1988, Nor-binakorphimine, a highly selective kappa-opioid antagonist in analgesic and receptor binding assays, J. Pharmacol. Exp. Ther. 246, 255.
32. 9-tetrahydrocannabinol in mice, Eur. J. Pharmacol. 260, 5.
33. 9-tetrahydrocannabinol in rats, Eur. J. Pharmacol. 70, 219.
34. Vaysse, P.J.J., E.L. Gardner and R.S. Zukin, 1987, Modulation of rat brain opioid receptors by cannabinoids, J. Pharmacol. Exp. Ther. 241, 534.
35. 9-THC) leads to changes in opioid-related behavioural patterns in rats, Brain Res. 680, 142.
36. Vela, G., M. Ruiz-Gayo and J.A. Fuentes, 1995b, Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine, Neuropharmacology 34, 665.
37. Welch, S.P. 1993, Blockade of cannabinoid induced antinociception by binaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanineleucine, ICI 174,864 or naloxone in mice, J. Pharmacol. Exp. Ther. 265, 633.
38. Welch, S.P. and D.L. Stevens, 1992, Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice, J. Pharmacol. Exp. Ther. 262, 10.
39. Welch, S.P., C. Thomas and S. Patrick, 1995, Modulation of cannabinoid-inducd antinociception after intracerebroventricular versus intratheacl administration to mice: possible mechanisms for interaction with morphine, J. Pharmacol. Exp. Ther. 272, 310.
40. Wilson, R.S. and E.L. May, 1975, Analgesic properties of the tetrahydrocannabinols, their metabolites and analogs, J. Med. Chem. 18, 700.
41. Yaksh, T.L., 1981, The antinociceptive effets of intrathecally administered levonantradol and desacetyllevonantradol in the rat, J. Clin. Pharmacol. 21, 334s.